PDS appoints Paul Butler and Martin Slade
pharmafile | December 22, 2009 | Appointment | Manufacturing and Production | PDS, Pharmaceutical Development Services, appointment, manufacturing and production
Pharmaceutical Development Services Ltd (PDS) has expanded its API (Active Pharmaceutical Ingredient) auditing capability, appointing two new associates.
Paul Butler and Martin Slade join the pharmaceutical consultancy and both have extensive CVs with particular expertise in API auditing in Europe, India and China.
PDS managing director Michael Gamlen said: “Having Martin and Paul available to add to the PDS body of expertise represents a considerable opportunity and I had no hesitation in bringing them onto the team.
“We are finding that API is a very hot topic at the moment. Some pharmaceutical sourcing, particularly from Asia, is proving of variable quality, leading to increased regulatory scrutiny. API Supplier Auditing is a key element of the international effort to maintain pharmaceutical supply chain integrity and avoid problems with counterfeit products and adulterated APIs.”
Based in Nottingham and Beckenham in the UK and South Carolina in the US, PDS plans further expansion in the New Year.
Related Content

Bio-Techne opens GMP small-molecule manufacturing facility in Bristol
Bio-Techne has opened a new facility in Bristol manufacturing Good Manufacturing Practice (GMP)-grade small molecules …

Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.






